Board summary
Key figures
26,976
Registered population
49.1% aged 18–64
36.0%
Aged 65+
ICB 21.9% · England 17.9%
4.1%
Ethnic minority (non-White)
1.6% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,117
Hypertension register
+2.27% in 3 yrs · England +5.60%
358
SMI register
28.3% of Lewes'
689
COPD register
Reviews +8.06% in 3 yrs
Forecast to 2030
6,537
Hypertension patients, 2030
+420 on today
69.9%
QRISK ≥20% on statins, 2030
+5.14pp over 3 yrs
8.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England and ICB.
Across 2,152 asthma patients, 47.0% had an annual review against 65.7% in England, a scale gap of 1,141 that may reflect recall bottlenecks.
Under-80 blood pressure control lags and fell.
Under-80 blood pressure control is 58.6% (England 67.8%), falling 6.2% over 2023 to 2025 (England +3.2%), with Seaford Medical Practice at 52.8% and Old.
Breast screening coverage exceeds local and national rates.
Breast screening coverage aged 53 to 70 is 76.9% against 75.1% in Lewes and 69.9% in England, rising +10.4% over 2023 to 2024.
Population, age and ethnicity
Patients aged 65+ comprise 36.0% of the PCN, well above England's 17.9%
Seaford PCN serves 26,976 registered patients across Seaford Medical Practice (18,216) and Old School Surgery (8,760). Patients aged 65+ comprise 36.0% (9,713 patients), well above Lewes (25.9%), NHS Sussex Integrated Care Board (21.9%) and England (17.9%). Working-age adults (18-64) make up 49.1% and children (0-17) 14.8%. Census usual residents in associated areas are 95.9% White, compared with 94.2% in Lewes, 91.0% in the ICB and 81.1% in England, with a 4.1% ethnic minority share. Age bands reflect registered patients, whereas ethnicity measures Census residents in surrounding areas.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Lewes local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Lewes LA) | 2,359 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Lewes LA) | 1,111 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Lewes LA) | 15.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 covers 0.0% of patients across both practices, with average IMD decile 7.0
Seaford PCN averages IMD decile 7.0 (England 5.5, Lewes 6.2, NHS Sussex Integrated Care Board 6.1) with 0.0% Core20 share (England 21.0%). Practice shares reconcile at 0.0%: Seaford Medical Practice and Old School Surgery both record 0.0% concentration and 0 estimated Core20 patients. Zero national decile 1 or 2 areas does not rule out household deprivation, and clinical vulnerability persists outside area metrics, including 3,925 adults on the depression register (16.8% versus 14.3% in England). Inequalities work could prioritise proactive clinical register reviews rather than area deprivation targeting.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
358
SMI register
1.31% recorded prevalence
154
Learning disability register
0.56% recorded prevalence
22
Care homes, 618 beds
In the PCN catchment
9.9%
Provide unpaid care
Lewes, Census 2021
The PCN records 358 severe mental illness patients (1.3%; England 1.0%) and 154 on the learning disability register (0.6%; England 0.6%). Catchment services contain 22 care homes with 618 beds. In the autumn 2025 snapshot, Lewes borough recorded 15 people sleeping rough, alongside a 9.9% unpaid care rate (a 2,671 PCN ceiling). Higher recorded severe mental illness prevalence could indicate greater review demand, testable through workload audits.
Severe mental illness: physical health checks
Recorded SMI physical checks trail benchmarks: 79.3% had blood pressure checked (England 83.4%) and 78.7% BMI recorded (England 82.1%). Lower blood pressure check completion at Seaford Medical Practice (75.8%) may reflect monitoring bottlenecks, testable through audits.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,117
Hypertension register
+2.27%
Register growth, 3 yrs
Lewes +5.23% · England +5.60%
−3.87pp
BP control, under 80
≤140/90 · +2.65pp aged 80+
+420
More patients by 2030
Forecast 6,537 (23.36%)
Hypertension case-finding and control
Hypertension prevalence is 22.3% (6,117 patients), above Lewes (18.1%), NHS Sussex Integrated Care Board (16.3%) and England (15.2%). While 89.2% of patients had a recent blood pressure reading, blood pressure control in patients aged under 80 is 58.6%, trailing Lewes (60.9%), the ICB (66.8%) and England (67.8%). Over 2023 to 2025, under-80 control fell 3.9 pp (England +2.1 pp), a relative drop of 6.2% (England +3.2%). Across practices, control reaches 69.1% at Old School Surgery but drops to 52.8% at Seaford Medical Practice. Lower blood pressure control despite high monitoring could reflect treatment titration bottlenecks, testable through a treatment escalation audit for patients under 80.
Lipids and statins
For patients with QRISK ≥ 20%, 58.0% receive lipid-lowering therapy, below England (63.6%) and NHS Sussex Integrated Care Board (60.0%), though above Lewes (56.2%). Lower treatment rates than England could reflect primary prevention review gaps, testable via clinical recall audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 51,350 | £2.40 | £2.42 | £1.86 | £123,240 |
| Cardiovascular (all), 2025 | 71,728 | £3.88 | £3.32 | £3.33 | £278,305 |
For lipid-regulating drugs in 2026, the PCN prescribed 51,350 items at £2.40 per item (Lewes £2.34, NHS Sussex Integrated Care Board £2.42, England £1.86), spending £27,729 more than at England's unit cost. Unit costs exceed England benchmarks, though this cost indicator does not measure prescribing efficiency, case-mix or formulary appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+0.78%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.54%
Asthma prevalence, PCN 3-yr % change
Across 2,152 registered asthma patients (8.2% prevalence versus 6.6% in England), only 47.0% had an annual review (England 65.7%), leaving an unreviewed gap of 1,141 patients. COPD reviews also trail at 64.2% across 689 patients (England 76.4%). For patients aged 5-19, asthma prescribing is 1,860 items per 1,000 (England 1,488), while second-hand smoke status recording (ages 6-19) is 65.3% (England 78.8%). This pattern could reflect preventative review bottlenecks, testable through local audit.
Cancer register and children's immunisation
Cancer register prevalence is 7.5% (2,042 patients; England 3.8%). In Q1 2025/26 childhood immunisations, MMR dose 1 coverage at 24 months is 89.2%, below the 95.0% target by 5.8 pp (NHS Sussex ICB 90.2%). At age 5, MMR dose 1 reaches 98.1% while dose 2 is 92.6%, a 5.5 pp difference below dose 1 (target 95.0%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In NHS Sussex ICB, 58.5% of staged cancers (4,799 of 8,209) were diagnosed at stage 1 or 2 in 2022, above England (55.3%) but 16.5 pp below the 75.0% national ambition. Known-stage completeness was 64.3% (8,209 of 12,766 cancers; England 67.0%). Closing this gap requires about 1,360 additional early-stage diagnoses annually across the ICB. These system figures do not measure PCN performance. In SEAFORD PCN, cancer prevalence is 7.5% (2,042 patients; England 3.8%), while cervical screening (25-49 years) is 72.8% (England 66.8%) but fell 2.8% over 2023 to 2025 (England -1.0%). Wider system staging shortfalls make primary care screening and early identification essential.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At East Sussex Healthcare NHS Trust, July 2026 provisional performance was 67.0% on the 62-day referral to treatment standard, trailing the 85.0% standard, NHS Surrey and Sussex Integrated Care Board (71.5%), and England (71.2%). University Hospitals Sussex NHS Foundation Trust was 65.2% and Maidstone and Tunbridge Wells NHS Trust was 87.4%. Conversely, the trust met the 28-day faster diagnosis standard at 84.2% (standard 75.0%; England 79.3%) and the 31-day combined standard at 98.2% (standard 96.0%; England 92.5%). Diagnostic waits over 6 weeks across all tests were 5.3% (England 23.1%), though echocardiography stood at 21.9%.
| Pathways within standard (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 84.20 | 74.01 | 81.78 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.19 | 76.79 | 98.35 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 67.04 | 65.20 | 87.43 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 6.48 | 5.62 | 0.92 | 21.40 |
| CT | 0.48 | 8.57 | 0.51 | 9.92 |
| Echocardiography | 21.94 | 0.39 | 2.57 | 28.48 |
| Colonoscopy | 0.74 | 39.35 | 19.80 | 30.83 |
| Gastroscopy | 0.31 | 20.02 | 24.03 | 29.02 |
| All 15 DM01 tests | 5.27 | 12.95 | 6.42 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In East Sussex, provisional June 2026 data shows 105,045 community care activities and 100,740 care contacts across 25,880 patients, with 17,285 referrals for 11,625 patients. Adults aged 65+ accounted for 68% of resident contacts (68,465 of 100,740). Across NHS Surrey and Sussex Integrated Care Board, activity reached 316,320 care activities and 309,615 care contacts.
Practice variation and patient experience
Patient satisfaction diverges by 24.9 pp between practices despite high clinical QOF achievement
In 2025/26, overall QOF achievement was 95.0% at Old School Surgery and 93.8% at Seaford Medical Practice (England 92.5%). Vaccination achievement reached 50.8% at Seaford Medical Practice, while achievement at Old School Surgery was 55.9%, spanning a practice range of 5.1 pp.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Seaford Medical | 105 | 0.0 | 37.7% | 79.0% | 79.8% |
| Old School Surgery | 122 | 0.0 | 47.5% | 66.0% | 54.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seventeen of 25 tracked measures trailed England's three-year change, led by dementia
Across 25 tracked measures, 17 trailed England on three-year change. Over 2023 to 2025, dementia prevalence fell 13.9% (England +6.0%), under-80 blood pressure control fell 6.2% (England +3.2%), diabetes HbA1c control without frailty fell 4.6% (England +4.4%), and COPD prevalence fell 4.8% (England +2.6%). Gains outpaced England in QRISK ≥ 20% lipid therapy (+9.7% versus +6.2%) and COPD reviews (+8.1% versus +2.8%) over 2023 to 2025, and breast screening over 2023 to 2024 (+10.4% versus +8.4%). Slower register change and declining clinical control could reflect review bottlenecks, testable through targeted clinical audits.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
BP control, under 80
Diabetes HbA1c control
COPD register
Hypertension treated to target
COPD reviews
QRISK statin treatment
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Lewes | Asset | PCN | Lewes |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (618 beds) | n/a | Schools (catchment) | 32 | n/a |
| Children's centres | no data | 2 | Places of worship | 30 | 76 |
| Libraries | n/a | 3 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 5 | 16 | Primary academies | 2 | 9 |
| Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Across 2,152 asthma patients (8.2% prevalence), 47.0% had a review versus 57.0% in Lewes, 62.5% in the ICB and 65.7% in England, a scale gap of 1,141 patients. For discussion: establish a standardised asthma review template and proactive recall alongside inhaler prescribing reviews across both practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension titration recall
Under-80 blood pressure control is 58.6% versus 60.9% in Lewes, 66.8% in the ICB and 67.8% in England, falling 3.9 pp over 2023 to 2025 (England +2.1 pp). For discussion: run a clinical pharmacist recall and medicines titration audit for uncontrolled patients under 80, starting at Seaford Medical Practice. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Dementia and SMI register audit
Dementia prevalence (1.6%, 426 patients) fell 13.9% over 2023 to 2025 (England +6.0%), while SMI blood pressure checks sit at 79.3% across 358 patients (England 83.4%). For discussion: audit dementia coding across care-home residents and combine annual SMI physical health checks with proactive outreach. Moderate effort to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Clinical audits for hidden vulnerability (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR catch-up audit (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Access and booking workflow review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80 hypertension titration recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Dementia and SMI register audit (p12) | Dementia register · Dementia: QOF prevalence · Severe mental illness register | 66.7% diagnosis ambition · 95% care plan 2027 · MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
